Department of Hematology and Oncology, Institute of Clinical Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, 60488 Frankfurt am Main, Germany.
Br J Cancer. 2013 Feb 5;108(2):265-70. doi: 10.1038/bjc.2012.555. Epub 2013 Jan 17.
This study was designed to compare cisplatin/docetaxel with oxaliplatin/docetaxel in patients with advanced and metastatic non-small lung cancer as a first-line treatment.
Patients were randomly assigned to receive either cisplatin 75 mg m(-2) and docetaxel 75 mg m(-2) every 3 weeks or oxaliplatin 85 mg m(-2) and docetaxel 50 mg m(-2) every 2 weeks. The primary end point was response rate, and secondary end points were toxicity, time to progression and overall survival.
A total of 88 patients (median age: 65 (39-86) years; stage IV: 93%) were randomly assigned. Response rate (complete and partial response) was 47% (95% CI: 33-61%) in the cisplatin/docetaxel arm and 28% (95% CI: 17-43%) in the oxaliplatin/docetaxel arm (P=0.118). There was no significant difference in time to progression (6.3 vs 4.9 months, P=0.111) and median overall survival (11.6 vs 7.0 months, P=0.102) with cisplatin/docetaxel vs oxaliplatin/docetaxel, although slight trends favouring cisplatin were seen. Oxaliplatin/docetaxel was associated with significantly less (any grade) renal toxicity (56% vs 11%), any grade fatigue (81% vs 59%), complete alopecia (76% vs 27%), any grade leukopenia (84% vs 61%) and grade 3/4 leukopenia (44% vs 14%) and neutropenia (56% vs 27%).
Oxaliplatin/docetaxel has activity in metastatic non-small cell lung cancer, but it seems to be inferior to cisplatin/docetaxel.
本研究旨在比较顺铂/多西他赛与奥沙利铂/多西他赛在晚期和转移性非小细胞肺癌患者中的一线治疗效果。
患者被随机分配接受顺铂 75 mg/m² 和多西他赛 75 mg/m²，每 3 周一次，或奥沙利铂 85 mg/m² 和多西他赛 50 mg/m²，每 2 周一次。主要终点是缓解率，次要终点是毒性、无进展生存期和总生存期。
共 88 例患者（中位年龄：65 岁[39-86 岁]；IV 期：93%）被随机分配。顺铂/多西他赛组的缓解率（完全和部分缓解）为 47%（95%CI：33-61%），奥沙利铂/多西他赛组为 28%（95%CI：17-43%）（P=0.118）。顺铂/多西他赛组与奥沙利铂/多西他赛组的无进展生存期（6.3 个月 vs 4.9 个月，P=0.111）和中位总生存期（11.6 个月 vs 7.0 个月，P=0.102）无显著差异，尽管顺铂有轻微的优势趋势。奥沙利铂/多西他赛组的肾毒性（任何等级）（56% vs 11%）、任何等级的乏力（81% vs 59%）、完全脱发（76% vs 27%）、任何等级的白细胞减少（84% vs 61%）和 3/4 级白细胞减少（44% vs 14%）和中性粒细胞减少症（56% vs 27%）的发生率明显较低。
奥沙利铂/多西他赛在转移性非小细胞肺癌中具有活性，但似乎不如顺铂/多西他赛。
